Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Stopped early · Phase 2

Conditions studied: Melanoma

In brief

The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.

Key facts

Study ID

NCT01709162

Run by

Bristol-Myers Squibb

People needed

31

Starts

2013-03-01

Expected to finish

2014-07-01

Last updated by the study team

2015-11-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Birmingham Hematology & Oncology Associates Llc — Birmingham, Alabama, United States
• Rocky Mountain Cancer Centers — Aurora, Colorado, United States
• Investigative Clinical Research Of Indiana, Llc — Indianapolis, Indiana, United States
• Cancer Center Of Kansas — Wichita, Kansas, United States
• Comprehensive Cancer Center Of Nevada — Las Vegas, Nevada, United States
• Lehigh Valley Hospital — Allentown, Pennsylvania, United States
• Texas Oncology Sammons Cancer Center — Dallas, Texas, United States
• Local Institution — Vienna, Austria
• Local Institution — Bordeaux, France
• Local Institution — Nantes, France
• Local Institution — Paris, France
• Local Institution — Cologne, Germany
• Local Institution — Erfurt, Germany
• Local Institution — Göttingen, Germany
• Local Institution — Heidelberg, Germany
• Local Institution — Kiel, Germany
• Local Institution — Siena, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.